Although cross-talk between Notch1 and Wnt/β-catenin signaling has previously been implicated in various cancers, the specific involvement of Notch3 in regulating β-catenin activity in EGFR-mutant NSCLC has not been reported, and the therapeutic benefit of direct β-catenin targeting in the context of EGFR TKIs have not been previously shown49,50. This evidence concerns the gene NOTCH1 and cancer.